Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Neurogene Inc. (NASDAQ:NGNE) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $44.00.

A number of analysts have recently issued reports on NGNE shares. Wall Street Zen downgraded shares of Neurogene from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Canaccord Genuity Group began coverage on Neurogene in a research report on Friday, February 27th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a report on Tuesday, January 13th. Finally, Lifesci Capital began coverage on Neurogene in a research report on Monday, January 26th. They set an “outperform” rating and a $50.00 price objective on the stock.

Institutional Trading of Neurogene

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its position in Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after acquiring an additional 978 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of Neurogene during the fourth quarter worth approximately $66,000. PNC Financial Services Group Inc. lifted its holdings in shares of Neurogene by 43.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after acquiring an additional 1,232 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after acquiring an additional 1,059 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Neurogene in the 4th quarter valued at $165,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Neurogene Price Performance

Shares of NASDAQ:NGNE opened at $23.60 on Tuesday. The company’s fifty day moving average price is $18.92 and its 200-day moving average price is $21.54. The firm has a market capitalization of $365.56 million, a price-to-earnings ratio of -5.74 and a beta of 1.53. Neurogene has a one year low of $6.88 and a one year high of $37.27.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.